Wealth Dimensions Group Ltd. Sells 181 Shares of AstraZeneca PLC (NASDAQ:AZN)

Wealth Dimensions Group Ltd. trimmed its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,395 shares of the company’s stock after selling 181 shares during the period. Wealth Dimensions Group Ltd.’s holdings in AstraZeneca were worth $420,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. CANADA LIFE ASSURANCE Co raised its position in AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares during the last quarter. Toronto Dominion Bank lifted its stake in AstraZeneca by 15.2% in the first quarter. Toronto Dominion Bank now owns 18,493 shares of the company’s stock worth $1,253,000 after acquiring an additional 2,447 shares during the period. Silvercrest Asset Management Group LLC boosted its holdings in AstraZeneca by 65.5% in the first quarter. Silvercrest Asset Management Group LLC now owns 39,915 shares of the company’s stock valued at $2,704,000 after acquiring an additional 15,794 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in AstraZeneca during the 1st quarter valued at $914,000. Finally, B. Riley Wealth Advisors Inc. raised its holdings in AstraZeneca by 36.0% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 23,504 shares of the company’s stock worth $1,592,000 after purchasing an additional 6,224 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on AZN shares. TD Cowen boosted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

Shares of AZN opened at $65.63 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a market cap of $203.49 billion, a price-to-earnings ratio of 31.40, a P/E/G ratio of 1.20 and a beta of 0.47. The business’s fifty day simple moving average is $73.44 and its two-hundred day simple moving average is $77.80.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same period in the previous year, the business earned $0.87 EPS. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. Research analysts anticipate that AstraZeneca PLC will post 4.1 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.